VibeOne Due Diligence
Challenges with diligence today
Under pressure
Deals are competitive, so diligence has to move fast. The first team to a clear view gets to the deal table.
Too many documents
Non-confidential decks, VDRs and public databases all have to be found, read and reconciled.
Laborious and costly
Each review needs experts in every functional area, pulled away from their day-to-day work.
High stakes
A deal turns on a few risks and opportunities. The review has to get to the heart of them.
General AI can't help
General AI can't plug into VDRs, and misses the nuance of the risks and opportunities that make or break a deal.
Faster answers, in one place, on your terms
First to the deal table
Review assets 8x faster and get to the deal table first. Reach a view on an asset while competing bidders are still working through the data room.
All the data in one place
Every source in one analysis, from public data to VDRs and subscription databases. Each finding links back to its source document.
Scale without added headcount
Screen more assets across more therapeutic areas with the same team. Use AI for the first-pass review and cut reliance on internal experts by 75%.
Validated by PhDs
Every analysis is built and cross-checked by Vibe Bio's PhD drug development team. VibeOne is trained to surface nuanced risks and opportunities, drawing on the experience of real drug developers.
Risk, differentiation and opportunity for every asset
Review the overall risk and how the asset compares with standard of care. Every dimension links to a deep dive, and gaps stay flagged as open items.
See how the asset compares with the competition
Get a snapshot of the asset against standard of care and individual pipeline competitors, with a conclusion, the data table and a reference for every figure.
| Attribute | ABC-482 Allogeneic CAR-T · Ph 1/2 | Standard of care Salvage chemo, then HSCT | Competitor A Autologous CAR-T · Ph 2 | Competitor B Anti-CD38 antibody · Ph 2 |
|---|---|---|---|---|
| Target | CD7 [1] | Non-targeted [2] | CD7 [3] | CD38 [4] |
| Complete response | 78% (n=23) [1] | 31–36% [2] | 85% (n=40) [3] | 41% (n=27) [4] |
| Time to treatment | Off the shelf [1] | Immediate [2] | 4–6 weeks manufacturing [3] | Off the shelf [4] |
| Dosing | Single IV infusion [1] | Multi-cycle IV [2] | Single IV infusion [3] | IV every 2 weeks [4] |
| ABC-482 vs. comparator | — | Differentiated | Partly differentiated | Differentiated |
Diligencing assets at scale to accelerate BD deals
Nonprofit biotech accelerator. CGTxchange is its marketplace for clinical-stage cell and gene therapy programs.
Pharma & investors are looking for assets, but are uncertain which programs on the marketplace are worth it.
VibeOne Due Diligence analyzed the data room for every asset listed on the marketplace using a rigorous set of criteria to help buyers find the best assets.
OTXL adopted VibeOne as the standard for every CGTxchange listing.